Global Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2020-2026

  • receipt Report ID : 24678
  • calendar_today Published On: Apr, 2020
  • file_copy Pages: 147
  • list Pharmaceuticals and Healthcare

Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.

The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

The global Duchenne Muscular Dystrophy Drugs market is valued at xx million US$ In 2020 and will reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2020-2026. The objectives of this study are to define, segment, and project the size of the Duchenne Muscular Dystrophy Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Duchenne Muscular Dystrophy Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Duchenne Muscular Dystrophy Drugs in these regions.

This research report categorizes the global Duchenne Muscular Dystrophy Drugs market by top players/brands, region, type and end user. This report also studies the global Duchenne Muscular Dystrophy Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Akashi Therapeutics Inc

Antisense Therapeutics Ltd

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

BioMarin Pharmaceutical Inc

Biophytis SAS

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Genethon SA

GTx Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

WAVE Life Sciences Ltd

Market size by Product

Development & Drug Target

Mechanism of Action (MoA)

Route of Administration (RoA)

Molecule Type

Market size by End User

Hospitals and Clinics

Medical Laboratories

Others

Market size by Region

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Europe

Germany

France

UK

Italy

Spain

Russia

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Duchenne Muscular Dystrophy Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2015 to 2019, and forecast to 2026.

To understand the structure of Duchenne Muscular Dystrophy Drugs market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Duchenne Muscular Dystrophy Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Duchenne Muscular Dystrophy Drugs submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Drugs are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Duchenne Muscular Dystrophy Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Study Coverage

1.1 Duchenne Muscular Dystrophy Drugs Product

1.2 Market Segments

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Product

1.4.2 Development & Drug Target

1.4.3 Mechanism of Action (MoA)

1.4.4 Route of Administration (RoA)

1.4.5 Molecule Type

1.5 Market by End User

1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by End User

1.5.2 Hospitals and Clinics

1.5.3 Medical Laboratories

1.5.4 Others

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global Duchenne Muscular Dystrophy Drugs Market Size

2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2015-2026

2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026

2.2 Duchenne Muscular Dystrophy Drugs Growth Rate by Regions

2.2.1 Global Duchenne Muscular Dystrophy Drugs Sales by Regions

2.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers

3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers

3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers

3.1.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)

3.2 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers

3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020)

3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)

3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers

3.4 Duchenne Muscular Dystrophy Drugs Manufacturing Base Distribution, Product Types

3.4.1 Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Duchenne Muscular Dystrophy Drugs Product Type

3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market

3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Duchenne Muscular Dystrophy Drugs Sales by Product

4.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Product

4.3 Duchenne Muscular Dystrophy Drugs Price by Product

5 Breakdown Data by End User

5.1 Overview

5.2 Global Duchenne Muscular Dystrophy Drugs Breakdown Data by End User

6 North America

6.1 North America Duchenne Muscular Dystrophy Drugs by Countries

6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Countries

6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Countries

6.1.3 United States

6.1.4 Canada

6.1.5 Mexico

6.2 North America Duchenne Muscular Dystrophy Drugs by Product

6.3 North America Duchenne Muscular Dystrophy Drugs by End User

7 Europe

7.1 Europe Duchenne Muscular Dystrophy Drugs by Countries

7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Countries

7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries

7.1.3 Germany

7.1.4 France

7.1.5 UK

7.1.6 Italy

7.1.7 Russia

7.2 Europe Duchenne Muscular Dystrophy Drugs by Product

7.3 Europe Duchenne Muscular Dystrophy Drugs by End User

8 Asia Pacific

8.1 Asia Pacific Duchenne Muscular Dystrophy Drugs by Countries

8.1.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries

8.1.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries

8.1.3 China

8.1.4 Japan

8.1.5 Korea

8.1.6 India

8.1.7 Australia

8.1.8 Indonesia

8.1.9 Malaysia

8.1.10 Philippines

8.1.11 Thailand

8.1.12 Vietnam

8.1.13 Singapore

8.2 Asia Pacific Duchenne Muscular Dystrophy Drugs by Product

8.3 Asia Pacific Duchenne Muscular Dystrophy Drugs by End User

9 Central & South America

9.1 Central & South America Duchenne Muscular Dystrophy Drugs by Countries

9.1.1 Central & South America Duchenne Muscular Dystrophy Drugs Sales by Countries

9.1.2 Central & South America Duchenne Muscular Dystrophy Drugs Revenue by Countries

9.1.3 Brazil

9.2 Central & South America Duchenne Muscular Dystrophy Drugs by Product

9.3 Central & South America Duchenne Muscular Dystrophy Drugs by End User

10 Middle East and Africa

10.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Countries

10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries

10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries

10.1.3 GCC Countries

10.1.4 Turkey

10.1.5 Egypt

10.1.6 South Africa

10.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Product

10.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs by End User

11 Company Profiles

11.1 Akashi Therapeutics Inc

11.1.1 Akashi Therapeutics Inc Company Details

11.1.2 Company Business Overview

11.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.1.5 Akashi Therapeutics Inc Recent Development

11.2 Antisense Therapeutics Ltd

11.2.1 Antisense Therapeutics Ltd Company Details

11.2.2 Company Business Overview

11.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.2.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Products Offered

11.2.5 Antisense Therapeutics Ltd Recent Development

11.3 Beech Tree Labs Inc

11.3.1 Beech Tree Labs Inc Company Details

11.3.2 Company Business Overview

11.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.3.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.3.5 Beech Tree Labs Inc Recent Development

11.4 Biogen Inc

11.4.1 Biogen Inc Company Details

11.4.2 Company Business Overview

11.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.4.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.4.5 Biogen Inc Recent Development

11.5 Bioleaders Corp

11.5.1 Bioleaders Corp Company Details

11.5.2 Company Business Overview

11.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.5.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Products Offered

11.5.5 Bioleaders Corp Recent Development

11.6 BioMarin Pharmaceutical Inc

11.6.1 BioMarin Pharmaceutical Inc Company Details

11.6.2 Company Business Overview

11.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.6.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.6.5 BioMarin Pharmaceutical Inc Recent Development

11.7 Biophytis SAS

11.7.1 Biophytis SAS Company Details

11.7.2 Company Business Overview

11.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.7.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Products Offered

11.7.5 Biophytis SAS Recent Development

11.8 Capricor Therapeutics Inc

11.8.1 Capricor Therapeutics Inc Company Details

11.8.2 Company Business Overview

11.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.8.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.8.5 Capricor Therapeutics Inc Recent Development

11.9 Catabasis Pharmaceuticals Inc

11.9.1 Catabasis Pharmaceuticals Inc Company Details

11.9.2 Company Business Overview

11.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.9.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Products Offered

11.9.5 Catabasis Pharmaceuticals Inc Recent Development

11.10 CRISPR Therapeutics

11.10.1 CRISPR Therapeutics Company Details

11.10.2 Company Business Overview

11.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)

11.10.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Products Offered

11.10.5 CRISPR Therapeutics Recent Development

11.11 Cumberland Pharmaceuticals Inc

11.12 Daiichi Sankyo Co Ltd

11.13 Debiopharm International SA

11.14 Editas Medicine Inc

11.15 Eloxx Pharmaceuticals Inc

11.16 F. Hoffmann-La Roche Ltd

11.17 FibroGen Inc

11.18 Fulcrum Therapeutics Inc

11.19 Galapagos NV

11.20 Genethon SA

11.21 GTx Inc

11.22 Santhera Pharmaceuticals Holding AG

11.23 Sarepta Therapeutics Inc

11.24 SOM Biotech SL

11.25 Strykagen Corp

11.26 Summit Therapeutics Plc

11.27 Taiho Pharmaceutical Co Ltd

11.28 Teijin Pharma Ltd

11.29 WAVE Life Sciences Ltd

12 Future Forecast

12.1 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions

12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2019-2025

12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2019-2025

12.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Product

12.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Product 2019-2025

12.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Product 2019-2025

12.3 Duchenne Muscular Dystrophy Drugs Market Forecast by End User

12.4 North America Duchenne Muscular Dystrophy Drugs Forecast

12.5 Europe Duchenne Muscular Dystrophy Drugs Forecast

12.6 Asia Pacific Duchenne Muscular Dystrophy Drugs Forecast

12.7 Central & South America Duchenne Muscular Dystrophy Drugs Forecast

12.8 Middle East and Africa Duchenne Muscular Dystrophy Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis

14.2 Duchenne Muscular Dystrophy Drugs Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

16.3 Disclaimer

List of Tables and Figures

Figure Duchenne Muscular Dystrophy Drugs Product Picture

Table Duchenne Muscular Dystrophy Drugs Market Segments

Table Key Manufacturers Duchenne Muscular Dystr